AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05164120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing 0mg of API
Trial: NCT05698329
Drug: AIV007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocular injection
Trial: NCT06160362
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
Trial: NCT05702463
Drug: Aspirin 81Mg Ec Tab twice daily for 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
Trial: NCT05676645
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: National policy recommendation for treatment of uncomplicated malaria in Uganda
Trial: NCT05938023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and scheduled as specified in the Arm description
Trial: NCT05308420
Drug: Intrathecal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
Trial: NCT05189535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05682170
Drug: ZN-d5 ZN-c3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agent
Trial: NCT05682170
Drug: ZN-c3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agent
Trial: NCT06644755
Drug: DS-2243a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE
Trial: NCT05381948
Drug: Eyp-1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection
Trial: NCT06175767
Drug: MT101-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06345495
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT05769595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04497168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo pills
Trial: NCT05748873
Drug: SPVN06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV-RdCVF-RdCVFL
Trial: NCT04390217
Drug: LB1148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
Trial: NCT04390217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
Trial: NCT05540938
Drug: Wangbi granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
Trial: NCT05577754
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
Trial: NCT05540938
Drug: Wangbi granules simulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
Trial: NCT05274568
Drug: [18F]UCB-2897
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container.
Trial: NCT05738486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04597424
Drug: Experimental: doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days.
Trial: NCT05044611
Drug: Anhydrous Amiloride Hydrochloride
RxNorm normalized name: amiloride hydrochloride, anhydrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase
Trial: NCT05044611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration : oral the control arm will receive a placebo twice daily during 2 months
Trial: NCT03962465
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal, administered on days 8 and 29
Trial: NCT06333314
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * mFOLFOX6 or FOLFIRI or XELOX regimen~* FOLFOX or XELOX or TFOX regimen~* FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.~* Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.~* Etoposide-cisplatin-doxorubicin or mitotane~* Cisplatin and gemcitabine or carboplatin and paclitaxel~* Etoposide-cisplatin or etoposide-carboplatin~* Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin.
Trial: NCT06200181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05478525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule BID for 14 days (n=4)
Trial: NCT05478525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules BID for 14 days (n=4)
Trial: NCT05478525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo capsules BID for 14 days (n=4)
Trial: NCT05034029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06584188
Drug: anti-inflammatory ketorolac tromethamine
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Intra- radicular anti-inflammatory {ketorolac tromethamine at room temperature}.~* Intra- radicular cold anti-inflammatory {ketorolac tromethamine at 2-5C}.
Trial: NCT00103831
Drug: Oral Taxane
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05607719
Drug: Bevespi
RxNorm normalized name: Bevespi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two puffs twice a day
Trial: NCT05607719
Drug: Bretzri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two puffs twice a day
Trial: NCT06498349
Drug: best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
Trial: NCT05289167
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg IV over 1 hour on Day +3 and +4
Trial: NCT06297629
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06561919
Drug: best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment according to widely accepted consensus Paper
Trial: NCT05667142
Drug: XEN1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 capsules
Trial: NCT05667142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT06103825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo :QD，PO，Day 1-Day 84
Trial: NCT05646563
Drug: NM8074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
Trial: NCT06191965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
Trial: NCT05895786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for PF-06823859
Trial: NCT05423106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as an oral formulation.
Trial: NCT05476094
Drug: Polyene Phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
Trial: NCT06186037
Drug: Mono drug group of Rosuvastatin 20 mg
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration once a day, taking it for 3 years
Trial: NCT05158244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily for 42 days
Trial: NCT06340581
Drug: Treatment A: BGF MDI HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Trial: NCT06340581
Drug: Treatment B: BGF MDI HFO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Trial: NCT06340581
Drug: Treatment C: BGF MDI HFO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
Trial: NCT05010707
Drug: Transdermal patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Trial: NCT05010707
Drug: Daily Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Trial: NCT05010707
Drug: BID Sublingual Tablet
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Trial: NCT05010707
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
Trial: NCT06269133
Drug: REGN2810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Trial: NCT06598046
Drug: Utidelone and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Utidelone: intravenous capecitabine: oral
Trial: NCT04733040
Drug: MOR202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR202 will be administered as an intravenous infusion
Trial: NCT05097287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection subcutaneous
Trial: NCT05192889
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV), oral (PO), or Intrathecal (IT).
Trial: NCT05192889
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given oral (PO).
Trial: NCT05192889
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV).
Trial: NCT05192889
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given oral (PO) or intravenously (IV).
Trial: NCT05192889
Drug: Intrathecal Triples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Intrathecal (IT).
Trial: NCT05177510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06018766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via dry powder inhaler
Trial: NCT06056245
Drug: Intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
Trial: NCT06056245
Drug: Post-operative
RxNorm normalized name: POUCH,DRAINABLE,POST-OPERATIVE H#9760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
Trial: NCT04473989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly subcutaneous administration of 40 ug
Trial: NCT04621981
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group was treated with normal saline.
Trial: NCT05361369
Drug: EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
Trial: NCT05384249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Trial: NCT06775379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Trial: NCT05021328
Drug: SBRT 7Gy✖️5 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT 7Gy✖️5 QD
Trial: NCT06091475
Drug: Other
RxNorm normalized name: others
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
Trial: NCT05613569
Drug: KLS-2031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLS-2031 administered by transforaminal epidural injection
Trial: NCT06343636
Drug: VG-3927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation
Trial: NCT06343636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation
Trial: NCT06343636
Drug: VG-3927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Dose Level
Trial: NCT04280523
Drug: ESR-specific PET scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level \[estradiol (E2)\], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1\~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
Trial: NCT05666518
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage at the discretion of the treating physician
Trial: NCT05238675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05155137
Drug: Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
Trial: NCT06780254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT05342376
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
Trial: NCT06761313
Drug: Triple combination formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks.
Trial: NCT05179252
Drug: Shen-Fu injection
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese patent medicine made by modern technology
Trial: NCT05179252
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline, used for sham control
Trial: NCT06010303
Drug: LBL-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBL-007 will be administered at a standard dose intravenously.
Trial: NCT04647435
Drug: APSCTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APSCTC + Toragesic® placebo + Tramal® placebo
Trial: NCT04647435
Drug: Toragesic®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APSCTC placebo + Toragesic® + Tramal® placebo
Trial: NCT06783192
Drug: MK-8527
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8527 capsule taken by mouth
Trial: NCT06783192
Drug: LNG/EE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG/EE combination tablet taken by mouth.
Trial: NCT06097468
Drug: NisinZ® P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut
Trial: NCT06493760
Drug: SSGJ-707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bispecific antibody
Trial: NCT06493760
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT00002102
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06786338
Drug: SGB-9768
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGB-9768 for subcutaneous (SC) injection
Trial: NCT06483802
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05075408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
Trial: NCT05997602
Drug: FCN-159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
Trial: NCT05829551
Drug: RAY1216 dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAY1216 dose 1 or Placebo